PT  - JOURNAL ARTICLE
AU  - N Hua
AU  - A Gomez
AU  - J Lindblom
AU  - G Von Perner
AU  - Y Enman
AU  - M Regardt
AU  - E Heintz
AU  - S Emamikia
AU  - D Grannas
AU  - I Parodis
TI  - PO.7.146 Sensitivity analysis of EQ-5D-3L index scores in relation to discriminative and known-groups validity in systemic lupus erythematosus
AID  - 10.1136/lupus-2022-elm2022.166
DP  - 2022 Oct 01
TA  - Lupus Science & Medicine
PG  - A109--A109
VI  - 9
IP  - Suppl 2
4099  - http://lupus.bmj.com/content/9/Suppl_2/A109.1.short
4100  - http://lupus.bmj.com/content/9/Suppl_2/A109.1.full
SO  - Lupus Sci Med2022 Oct 01; 9
AB  - Purpose To investigate the ability of different EQ-5D-3L index scores to discriminate between verum drug and placebo (discriminant validity) as well as between responders and non-responders (known-groups validity) in the SLE patient population of two phase III clinical trials of belimumab.Methods Data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (N = 1684), which both showed superiority of belimumab to placebo, were utilised. Responders were defined as SLE Responder Index 4 (SRI-4) achievers at week 52. The Pearson’s χ2 and Mann-Whitney U tests were used for comparisons, and logistic regression analysis was used for adjustments for confounders and assessment of independence.Results While full health state (FHS; EQ-5D index score 1) showed the best ability to discriminate between belimumab and placebo (adjusted OR: 1.47; 95% CI:1.1–2.0; P=0.008) and between SRI-4 responders and non-responders (adjusted OR: 3.47; 95% CI: 1.3–11.0; P=0.020), the discriminative ability of EQ-5D index scores 0.800 or more reached statistical significance for both discriminant validity (adjusted OR: 1.29; 95% CI: 1.0–1.6; P=0.036) and known-groups validity (adjusted OR: 3.08; 95% CI: 1.2–9.7; P=0.034).Conclusions Overall, higher EQ-5D index scores were associated with increasing ability to discriminate between belimumab and placebo, and between responders and non-responders. EQ-5D index scores less stringent than FHS may be clinically relevant treatment targets in patients with SLE, introducing the concept of EQ-5D adequate health state.